Myelo Therapeutics Receives Additional NIAID Funding to Advance Development of Myelo001 for Acute Radiation Syndrome

Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced today that the U.S. National Institute of Allergy and Infectious Diseases…

3 Min
More

Learnings from Covid-19 & Partnership Opportunities with Bayer G4A

Fr., 4. Juni · 17:00 MESZ

Details

Join one of our webinars to gain insights about this year’s partnership opportunities for digital health innovators with Bayer G4A!

We will reflect on the implications of the Covid-19 pandemic for digital health…

1 Min
More

The winner of the 2021 Speed Lecture Award is Bruna Seco from the Max Planck Institute of Colloids and Interfaces

Berlin, May 12, 2021 - Today the 15th Speed Lecture Award took place as part of BIONNALE, again as a live-stream and with over 750 registrations.

1 Min
More

Global Innovation Collaborative

A collaboration between Berlin, London, New York and Paris to leverage our collective innovation and speed our recovery from Covid-19

1 Min
More

Caresyntax Raises $100 Million to Make Surgery Smarter and Safer

Investment will strengthen technology and expand company’s reach

 

5 Min
More

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per…

3 Min
More

These are the Speed Lecture Award finalists 2021

What is the Speed Lecture Award?

Young scientists present in three minutes their new projects and ideas in life sciences and healthcare industries in front of the BIONNALE audience of more than 600 experts from academia, science and business.

1 Min
More

ProBioGen enters into Agreement with Nobelpharma for Manufacturing Process Development of their Vaccine Project

 

ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project.

Earlier work confirmed already the versatility and benefit of ProBioGen’s vaccine development platform, consisting of the…

1 Min
More

FyoniBio® the service branch of Glycotop

 

With beginning of 2021 Glycotope will offer its Contract Development Organization (CDO) and Clinical Lab services under the brand name FyoniBio®, the service branch of Glycotope.

With 20 years of history in biopharma development FyoniBio® is in a…

1 Min
More

ProBioGen licenses GlymaxX® Technology to Sanofi

Enhancement of Target Cell Killing for Innovative Therapies

2 Min
More
Show more items